Twist Bioscience Corporation
TWST · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.00 | 0.52 | -0.31 |
| FCF Yield | -4.49% | -2.64% | -14.77% | -11.91% |
| EV / EBITDA | -30.24 | -14.03 | -5.51 | -7.63 |
| Quality | ||||
| ROIC | -23.79% | -39.67% | -30.42% | -25.34% |
| Gross Margin | 50.72% | 42.61% | 36.61% | 41.38% |
| Cash Conversion Ratio | 0.61 | 0.31 | 0.70 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.39% | 15.42% | 22.81% | 31.22% |
| Free Cash Flow Growth | -9.34% | 59.37% | 24.75% | -62.41% |
| Safety | ||||
| Net Debt / EBITDA | 2.06 | 0.80 | 1.10 | 1.34 |
| Interest Coverage | 0.00 | -7,614.86 | -43,431.80 | -2,934.70 |
| Efficiency | ||||
| Inventory Turnover | 6.56 | 7.46 | 4.85 | 3.04 |
| Cash Conversion Cycle | 89.13 | 86.32 | 107.93 | 131.02 |